Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
JAMA Network Open|January 27, 2021
Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019Jeromie M Ballreich, Cary P Gross, Neil R Powe, et al.Plos One|November 13, 2019
Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costsIrene B Murimi-Worstell, Jeromie M Ballreich, Marissa J Seamans, et al.JAMA Health Forum|August 17, 2022
Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019Elizabeth Plummer, Mariana P Socal, Jeromie M Ballreich, et al.JAMA Health Forum|October 3, 2025
US Antibiotic Importation and Supply Chain VulnerabilitiesMariana P Socal, Yunxiang Sun, Jeromie M Ballreich, et al.Health Affairs (Project Hope)|March 3, 2025
Estimated Savings From Extending Prescription Drug Inflationary Rebates To All Commercial PlansMarissa B Reitsma, Stacie B Dusetzina, Jeromie M Ballreich, et al.JAMA Internal Medicine|April 17, 2023
Examining Opportunities to Increase Savings From Medicare Price NegotiationsMarissa B Reitsma, Stacie B Dusetzina, Jeromie M Ballreich, et al.Journal of Medical Economics|December 18, 2025
Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for painJeromie M Ballreich, Sushanth Jeyakumar, Kenna Garrison, et al.JAMA Network Open|January 16, 2019
Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial InsurersDora H Lin, Christopher M Jones, Wilson M Compton, et al.JAMA Network Open|January 16, 2019
Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private InsurersJames Heyward, Christopher M Jones, Wilson M Compton, et al.Pageof 1